Information  X 
Enter a valid email address

AstraZeneca PLC (AZN)

  Print      Mail a friend       Annual reports

Wednesday 03 April, 2019

AstraZeneca PLC

Director/PDMR Shareholding

RNS Number : 9870U
AstraZeneca PLC
03 April 2019
 

03 April 2019 10:00 BST

 

Transactions by Persons Discharging Managerial Responsibilities

Disclosure under Article 19 of the EU Market Abuse Regulation

 

AstraZeneca PLC (the Company) announces that, on 29 March 2019, awards of the Company's ordinary shares of $0.25 each (Ordinary Shares) vested to certain Persons Discharging Managerial Responsibilities of the Company (PDMRs) under the AstraZeneca Deferred Bonus Plan (AZDBP).

 

The AZDBP award was granted on 24 March 2016, following the deferral of a portion of each PDMR's annual bonus paid in respect of 2015 performance into Ordinary Shares, and vested on completion of the three-year holding period.

 

Following the withholding of shares to satisfy certain tax obligations arising on vesting, the PDMRs' beneficial interests in Ordinary Shares changed as detailed in the table below:

 

PDMR

Ordinary Shares acquired under the AZDBP

Pascal Soriot

15,755

Marc Dunoyer

4,838

 

For tax purposes, the fair market value of an Ordinary Share at vest was 6496 pence, being the closing price on the last trading day preceding the vesting.

 

Further details are set out in the attached notifications, made in accordance with the requirements of the EU Market Abuse Regulation.

 

 

About AstraZeneca

AstraZeneca is a global, science-led biopharmaceutical company that focuses on the discovery, development and commercialisation of prescription medicines, primarily for the treatment of diseases in three therapy areas - Oncology, Cardiovascular, Renal & Metabolism and Respiratory. AstraZeneca operates in over 100 countries and its innovative medicines are used by millions of patients worldwide. For more information, please visit astrazeneca.com and follow us on Twitter @AstraZeneca.

 

 

Media Relations

 

 

Gonzalo Viña

UK/Global

+44 203 749 5916

Rob Skelding

UK/Global

+44 203 749 5821

Matt Kent

UK/Global

+44 203 749 5906

Jennifer Hursit

UK/Global

+44 203 749 5762

Christina M Hägerstrand

Sweden

+46 8 552 53 106

Michele Meixell

US

+1 302 885 2677

 

 

 

Investor Relations

 

 

Thomas Kudsk Larsen

 

+44 203 749 5712

Henry Wheeler

Oncology

+44 203 749 5797

Christer Gruvris

BioPharma - Cardiovascular; Metabolism

+44 203 749 5711

Nick Stone

BioPharma - Respiratory; Renal

+44 203 749 5716

Josie Afolabi

Other

+44 203 749 5631

Craig Marks

Finance; Fixed Income

+44 7881 615 764

Jennifer Kretzmann

Retail Investors; Corporate Access

+44 203 749 5824

US toll-free

 

+1 866 381 72 77

 

Adrian Kemp
Company Secretary

AstraZeneca PLC

 

 

 

1

 

Details of the person discharging managerial responsibilities / person closely associated

a)

 

Name

Pascal Soriot

2

 

Reason for the notification

 

a)

 

Position/status

 

Chief Executive Officer

b)

 

Initial notification /Amendment

Initial notification

3

 

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

 

Name

AstraZeneca PLC

b)

 

LEI

PY6ZZQWO2IZFZC3IOL08

4i

 

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a)

 

Description of the financial instrument, type of instrument

 

Identification code

Ordinary Shares of US$0.25 each in AstraZeneca PLC

 

 

GB0009895292

 

b)

 

Nature of the transaction

 

 

Acquisition of ordinary shares pursuant to a vesting under the AstraZeneca Deferred Bonus Plan, for nil consideration.

c)

 

Price(s) and volume(s)

 

 

Price(s)

Volume(s)

0

15,755

 

d)

 

Aggregated information

 

- Aggregated volume

- Price

Not applicable - single transaction

 

 

 

 

e)

 

Date of the transaction

 

29 March 2019

f)

 

Place of the transaction

 

Outside a trading venue

 

 

1

 

Details of the person discharging managerial responsibilities / person closely associated

a)

 

Name

Marc Dunoyer

2

 

Reason for the notification

 

a)

 

Position/status

 

Chief Financial Officer

b)

 

Initial notification /Amendment

Initial notification

3

 

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

 

Name

AstraZeneca PLC

b)

 

LEI

PY6ZZQWO2IZFZC3IOL08

4i

 

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a)

 

Description of the financial instrument, type of instrument

 

Identification code

Ordinary Shares of US$0.25 each in AstraZeneca PLC

 

 

GB0009895292

 

b)

 

Nature of the transaction

 

 

Acquisition of ordinary shares pursuant to a vesting under the AstraZeneca Deferred Bonus Plan, for nil consideration.

c)

 

Price(s) and volume(s)

 

 

Price(s)

Volume(s)

0

4,838

 

d)

 

Aggregated information

 

- Aggregated volume

- Price

Not applicable - single transaction

 

 

 

 

e)

 

Date of the transaction

 

29 March 2019

f)

 

Place of the transaction

 

Outside a trading venue

 


This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.
 
END
 
 
DSHUOSWRKRASRRR

a d v e r t i s e m e n t